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Abstract
Autoimmune type 1 diabetes recurrence in pancreas 
grafts was first described 30 years ago, but it is not yet 
completely understood. In fact, the number of trans-
plants affected and possibly lost due to this disease 
may be falsely low. There may be insufficient aware-
ness to this entity by clinicians, leading to underdiag-
nosis. Some authors estimate that half of the immu-
nological losses in pancreas transplantation are due to 
autoimmunity. Pancreas biopsy is the gold standard for 
the definitive diagnosis. However, as an invasive proce-
dure, it is not the ideal approach to screen the disease. 
Pancreatic autoantibodies which may be detected early 
before graft dysfunction, when searched for, are prob-
ably the best initial tool to establish the diagnosis. The 
purpose of this review is to revisit the autoimmune 
aspects of type 1 diabetes and to analyse data about 
the identified autoantibodies, as serological markers of 
the disease. Therapeutic strategies used to control the 
disease, though with unsatisfactory results, are also ad-
dressed. In addition, the author’s own experience with 
the prospective monitoring of pancreatic autoantibodies 
after transplantation and its correlation with graft out-
come will be discussed.
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Core tip: Recurrence of pancreatic autoantibodies after 
kidney-pancreas transplantation is a disturbing find-
ing. It was estimated that half of the immunological 
losses of pancreas grafts may be due to autoimmunity. 
There is a rising investigational effort concerning this 
issue. At our unit, we have designed a protocol of pro-
spective monitoring of pancreatic autoantibodies after 
transplantation. In our experience, patients with posi-
tive pancreatic autoantibodies, compared to negative 
patients, were more likely to present higher HbA1c and 
lower C-peptide levels. A review of the most important 
publications in this field, and about the interest of pan-
creatic autoantibodies monitoring after transplantation, 
was made.
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TYPE 1 DIABETES MELLITUS AND 
AUTOIMMUNITY
Type 1 diabetes mellitus (DM1), a disease with an evident 
underlying autoimmune process[1], may recur after pancre-
as transplantation. The first cases described by Sutherland 
et al[2] were documented only in patients who have received 
grafts from highly HLA-matched donors (siblings) and 
with minimized immunosuppression[3]. Few years later, 
diabetes recurrence was also documented in recipients of  
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pancreas grafts with HLA-mismatches with the donor and 
maintaining standard immunosuppression[4].
There is a recognized genetic susceptibility for DM1. 
The disease is strongly associated with HLA genes, specif-
ically with alleles DR3 and DR4[5,6]; with polymorphisms 
of  the proinsulin/insulin gene[7]; and with the PTP gene 
(PTPN22), a gene coding for a lymphocyte-specific tyro-
sine phosphatase[8]. However, only about 50% of  HLA 
identical twins inheriting alleles DR3 and/or DR4 develop 
the disease[1,9]. It means that inheritance of  the HLA gene 
is not a sufficient condition and susceptibility is most cer-
tainly polygenic.
It is not known which individuals are at higher risk 
for DM1 recurrence on pancreas graft and what are the 
important risk factors for the disease. Additionally, there 
is also no consensus about the best screening tests to 
identify patients at risk.
DIAGNOSIS OF AUTOIMMUNE DIABETES 
RECURRENCE ON PANCREAS GRAFTS
A pancreas graft biopsy showing an inflammatory T-cell 
infiltrate, specifically targeting the beta-cells (aspect des-
ignated as “insulitis”) and sparing the exocrine tissue, re-
mains the gold-standard for the diagnosis of  DM1 recur-
rence[10]. However, it is not easy to justify such an invasive 
procedure, carrying a non neglectable risk of  complica-
tions, in patients without a misfunctioning pancreas graft-
or, at least, without reliable data favouring the hypothesis 
of  reactivated autoimmunity.
Serological markers of  the autoimmune process, the 
islet cell autoantibodies (ICA)[4] have been proposed as a 
basic tool, the first screening test to identify the activity 
of  autoimmune disease. The anti-glutamic acid decar-
boxylase (anti-GAD antibodies)[11]; the anti-insulin anti-
bodies (IAA)[12]; the anti-IA2 (anti-tyrosine phosphatase) 
antibodies[13]; and the most recently described anti-ZnT8 
(cation efflux zinc transporter) antibodies[14], have also 
been identified as autoimmune markers of  DM1. The 
positivity for these immune humoral markers is consid-
ered a good predictor of  the enhancement of  autoim-
mune diabetes. The association of  several markers (two 
or more) increases its predictive value[15]. As yet, pancreas 
biopsy is the confirmatory procedure when suspecting 
for recurrence on pancreas graft. 
There is some controversy about the real role of  these 
autoantibodies: do they have a direct participation in the 
process? Or are they surrogate markers, merely testifying 
the lesion? Although the pancreatic autoantibodies were 
not detected in a recent case documented with insulitis in 
the biopsy[16], they are usually present in the vast majority 
of  the cases confirmed by biopsy.
The new onset or rising levels of  these autoantibodies 
in pancreas transplant patients has been pointed out as 
a serious indicator of  recurrence and progression of  the 
disease. In fact, several studies reported worse pancreas 
outcome in patients with these humoral markers[10,17-20]. 
It has been suggested that half  of  the immune losses of  
pancreas grafts may be due to autoimmunity[21]. Based on 
these data, monitorization of  pancreatic autoantibodies 
has been recommended in all pancreas transplants[21] as 
a primary test to identify patients at risk for autoimmune 
graft loss. My personal opinion is concordant with these 
authors, stating that the disease may currently remain 
underdiagnosed. This may be the cause of  pancreas graft 
failure in some cases with unclear etiology, probably be-
cause this is not sufficiently investigated.
IMMUNOSUPPRESSION AND 
AUTOIMMUNITY
Immunosuppressive protocols designed to prevent rejec-
tion in the pancreas transplant are not capable of  con-
taining autoimmunity[21]. This is a disturbing finding in or-
gan transplantation. Remembering autoimmune disorders 
affecting the kidney, such as ANCA-associated vasculitis 
or lupus, they may relapse after kidney transplantation de-
spite apparently adequate immunosuppression to control 
alloimmunity. One condition in kidney transplantation, 
which is quite similar to the pancreatic autoimmunity 
recurrence, is that observed in some patients with Alport 
syndrome: they may develop anti-glomerular basement 
membrane disease post-transplantation, after a new expo-
sition to glomerular basement membrane antigens (type 4 
collagen antigens), for which they were natively defective. 
Immune attack against the newly presented beta-cells 
may occur after a pancreas transplant.
The Miami group has tried to treat autoimmune re-
lapse in pancreas transplants with anti-lymphocyte (anti-B 
and/or anti-T cell) therapies[21-23]. After a transient re-
sponse in a few cases, autoimmune activity has recurred 
within a short period of  time. At the time of  the second 
recurrence they were able to identify the same clone of  
autoreactive GAD-specific T cells which has been found 
in the first recurrence. Pancreatic autoantibodies fol-
lowed the reappearance of  the T cells, with a new rise[23]. 
Therefore, it seems that immunosuppressive agents avail-
able at the moment cannot prevent this immune memory 
response. To date, there are no studies reporting effective 
and sustained treatment of  pancreatic autoimmunity in 
DM1 patients with diabetes recurrence.
Efforts are needed to find therapeutic strategies to 
control this process. Can protocols used in kidney trans-
plant hypersensitized patients be advantageous? Com-
bined therapies, like plasmapheresis, immunoglobulin 
and rituximab have been successfully used in kidney 
transplants with HLA donor-specific antibodies; and also 
in systemic autoimmune diseases, such as lupus, with se-
vere expression. The results from trials using new drugs 
(abatacept, etanercept, teplizumab, rituximab) have failed 
to prove long lived efficacy in native pancreas after DM1 
onset[24]. However, intervention after clinical disease 
(tertiary intervention) may be too late, since overt dis-
ease corresponds to extensive beta-cell destruction. The 
most promising long-term results were achieved with 
hematopoietic stem-cell transplantation, in patients pre-
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senting autoimmune markers, but before clinical diabetes 
(secondary intervention)[24]. Another serious worry are 
the important side effects of  each drug. Toxicities and ef-
ficacy, if  used in combination, remain to be assessed. We 
have learned the benefits of  the association of  compli-
mentary therapies from the oncology research, allowing 
the use of  smaller doses, with fewer side effects and with 
gains in terms of  efficacy. Could this be an efficient strat-
egy in pancreas transplant patients with recurred autoim-
mune diabetes? 
OUR OWN EXPERIENCE
We have designed a prospective monitoring protocol of  
pancreatic autoantibodies after pancreas-kidney trans-
plantation at our unit. Anti-GAD, IAA and ICA were 
analysed before or on admission for transplantation, at 6 
and 12 mo, and at least once a year thereafter. In a cohort 
of  135 patients[25], 34.5% were positive for any of  these 
antibodies before surgery, anti-GAD being the most 
prevalent (> 20%). Nearly half  of  these became negative 
within months or years, but in some others (previously 
negative) we verified a new appearance of  anti-GAD an-
tibodies. After a mean time of  6 years (ranging from 1 to 
12 years), among the 78% of  the patients with function-
ing pancreas, 44% are positive for at least one autoanti-
body. Anti-GAD remain the most common (31%). The 
frequency of  patients with IAA before transplantation 
was surprisingly low, 3%, considering that patients under 
exogenous insulin may present anti-insulin antibodies. 
At our last follow-up the prevalence of  IAA-positive is 
three-fold higher and none of  the patients was under 
exogenous insulin. ICA, present in 10% of  the patients 
before transplantation, tended to disappear and there was 
no new onset of  these antibodies. Less than 3% maintain 
ICA positive now. In 10% of  the patients more than one 
pancreatic autoantibody was present. 
Pancreas graft survival was not significantly different 
in the group of  patients with some positive pancreatic 
autoantibody, compared to the patients who were nega-
tive for these autoantibodies. The immunosuppression 
used in the positive and in the negative patients did not 
differ (tacrolimus and mycophenolic acid mostly used) 
and the frequency of  patients withdrawn from steroids 
was also similar in both groups.
Positive patients for any pancreatic autoantibody 
tended to have a higher HLA-match with the donor, 
though not reaching statistical significance.
Concerning the glycemic control, our data are not 
so tranquilizing. The group of  patients with at least one 
positive pancreatic autoantibody, compared to nega-
tive patients, was more likely to have higher HbA1c and 
lower C-peptide levels and this difference was statistically 
significant. And, more important, our results showed a 
more than 5 times higher probability to find positive au-
toimmunity among the pancreas transplants with normal-
high HbA1c. Kidney graft function was similar in both 
groups, with or without pancreatic antibodies, which 
strengths the argument that decline in glycemic control 
was not due to alloimmunity. In a former report from our 
centre[26], analysing the glycemic profile in both groups 
(positive and negative for pancreatic autoantibodies), the 
difference did not (yet) reach statistical significance. In 
fact, in this former study, a few number of  patients with 
positive antibodies showed normal-high fasting glucose 
levels and the lowest C-peptide. Comparing results from 
our former study to the more recent one, it probably 
means that we are facing an evolutive process. The num-
ber of  patients has almost doubled and the follow-up 
period is now much longer, and we could now associate 
pancreatic autoimmunity with less favourable glycemic 
profile. It will be interesting to analyse data with a more 
extended follow-up.
CONCLUSION
In conclusion, we think it is advisable to routinely moni-
tor pancreatic autoantibodies after transplantation. There 
is substantial evidence that DM1 can reappear after pan-
creas transplantation, but may have been underdiagnosed 
for the last decades[21,27], mainly because it is a forgotten 
question. The awareness of  the entity will certainly lead 
the majority of  pancreas transplant units to search for 
the disease and to prospectively assess these antibod-
ies. Pancreas graft biopsy remains the gold standard for 
the diagnosis of  DM1 recurrence but, as it is an invasive 
procedure, it is not the ideal as a screening methodology, 
without other clinical or analytical (metabolic or immu-
nological) data. On the other hand, pancreas biopsy only 
after impaired endocrine function is most of  the times 
too late. Antibody monitoring is a non-invasive basic 
screening test, available in most units, and may bring the 
necessary information to proceed to pancreas biopsy 
before dysfunction. Islet autoantibodies are currently the 
most robust biomarker of  DM1[28].
Additionally, pancreatic autoantibodies assessment 
may be of  interest in other areas. The authors of  a very 
recent study[29] have also proposed the use of  the GAD-
autoantibody status before pancreas-kidney transplanta-
tion as a guide to choose the kind of  prophylactic anti-
body induction.
Positivity for pancreatic autoantibodies after transplan-
tation may never occur, or it may be intermittent or per-
sistent, not always correlated with graft function, at least 
in a short period of  time. However, beta-cell destruction 
was documented in other cases and autoantibody rising 
may have preceded in several years the graft dysfunction, 
has it been searched for. An early diagnosis gives the clini-
cian more time for some kind of  intervention.
Another critical point is the lack of  effectiveness of  
the treatments tried so far in DM1 patients. The recogni-
tion of  the role of  islet autoreactive CD4+ T cells[22,23] 
and CD8+ T cells[27,30] on beta-cell destruction, as well 
as all the targets of  humoral activity[28], may lead to other 
treatment opportunities. Novel therapies, namely target-
ing proinsulin-reactive CD8+ T cells, were recently pro-
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posed as a potential therapeutic approach[31]. 
In the meantime, we must improve our ability to make 
an early diagnosis and to increase our knowledge about 
all the processes of  the disease. These may be some of  
the missing steps to find the most advantageous strategy 
to treat, or even to prevent, the autoimmune diabetes re-
currence in pancreas grafts.
REFERENCES
1 Atkinson MA, Maclaren NK. The pathogenesis of insulin-de-
pendent diabetes mellitus. N Engl J Med 1994; 331: 1428-1436 
[PMID: 7969282 DOI: 10.1056/NEJM199411243312107]
2 Sutherland DE, Sibley R, Xu XZ, Michael A, Srikanta AM, 
Taub F, Najarian J, Goetz FC. Twin-to-twin pancreas trans-
plantation: reversal and reenactment of the pathogenesis 
of type I diabetes. Trans Assoc Am Physicians 1984; 97: 80-87 
[PMID: 6398950]
3 Sutherland DE, Goetz FC, Sibley RK. Recurrence of disease 
in pancreas transplants. Diabetes 1989; 38 Suppl 1: 85-87 
[PMID: 2642862 DOI: 10.2337/diab.38.1.S85]
4 Bosi E, Bottazzo GF, Secchi A, Pozza G, Shattock M, Saun-
ders A, Gelet A, Touraine JL, Traeger J, Dubernard JM. Islet 
cell autoimmunity in type I diabetic patients after HLA-mis-
matched pancreas transplantation. Diabetes 1989; 38 Suppl 1: 
82-84 [PMID: 2642861 DOI: 10.2337/diab.38.1.S82]
5 Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, Babu 
SR, Yu L, Miao D, Erlich HA, Fain PR, Barriga KJ, Norris 
JM, Rewers MJ, Eisenbarth GS. Extreme genetic risk for type 
1A diabetes. Proc Natl Acad Sci USA 2006; 103: 14074-14079 
[PMID: 16966600 DOI: 10.1073/pnas.0606349103]
6 Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. 
Cell 1996; 85: 291-297 [PMID: 8616883 DOI: 10.1016/S0092-
8674(00)81106-X]
7 Bell GI, Horita S, Karam JH. A polymorphic locus near the 
human insulin gene is associated with insulin-dependent 
diabetes mellitus. Diabetes 1984; 33: 176-183 [PMID: 6363172 
DOI: 10.2337/diab.33.2.176]
8 Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, 
Howson JM, Vella A, Nutland S, Rance HE, Maier L, Barratt 
BJ, Guja C, Ionescu-Tîrgoviste C, Savage DA, Dunger DB, 
Widmer B, Strachan DP, Ring SM, Walker N, Clayton DG, 
Twells RC, Gough SC, Todd JA. Replication of an association 
between the lymphoid tyrosine phosphatase locus (LYP/
PTPN22) with type 1 diabetes, and evidence for its role as 
a general autoimmunity locus. Diabetes 2004; 53: 3020-3023 
[PMID: 15504986 DOI: 10.2337/diabetes.53.11.3020]
9 Redondo MJ, Rewers M, Yu L, Garg S, Pilcher CC, Elliott 
RB, Eisenbarth GS. Genetic determination of islet cell auto-
immunity in monozygotic twin, dizygotic twin, and non-
twin siblings of patients with type 1 diabetes: prospective 
twin study. BMJ 1999; 318: 698-702 [PMID: 10074012 DOI: 
10.1136/bmj.318.7185.698]
10 Tydén G, Reinholt FP, Sundkvist G, Bolinder J. Recurrence 
of autoimmune diabetes mellitus in recipients of cadaveric 
pancreatic grafts. N Engl J Med 1996; 335: 860-863 [PMID: 
8778604 DOI: 10.1056/NEJM199609193351205]
11 Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena 
M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P. 
Identification of the 64K autoantigen in insulin-dependent 
diabetes as the GABA-synthesizing enzyme glutamic acid 
decarboxylase. Nature 1990; 347: 151-156 [PMID: 1697648 
DOI: 10.1038/347151a0]
12 Ziegler AG, Hillebrand B, Rabl W, Mayrhofer M, Hummel 
M, Mollenhauer U, Vordemann J, Lenz A, Standl E. On the 
appearance of islet associated autoimmunity in offspring of 
diabetic mothers: a prospective study from birth. Diabetologia 
1993; 36: 402-408 [PMID: 8314444 DOI: 10.1007/BF00402275]
13 Pietropaolo M, Hutton JC, Eisenbarth GS. Protein tyrosi-
ne phosphatase-like proteins: link with IDDM. Diabetes 
Care 1997; 20: 208-214 [PMID: 9118776 DOI: 10.2337/dia-
care.20.2.208]
14 Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, 
Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton 
JC. The cation efflux transporter ZnT8 (Slc30A8) is a major 
autoantigen in human type 1 diabetes. Proc Natl Acad Sci 
USA 2007; 104: 17040-17045 [PMID: 17942684 DOI: 10.1073/
pnas.0705894104]
15 Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jack-
son RA, Chase HP, Eisenbarth GS. Prediction of type I dia-
betes in first-degree relatives using a combination of insulin, 
GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 
45: 926-933 [PMID: 8666144 DOI: 10.2337/diab.45.7.926]
16 Assalino M, Genevay M, Morel P, Demuylder-Mischler 
S, Toso C, Berney T. Recurrence of type 1 diabetes after si-
multaneous pancreas-kidney transplantation in the absence 
of GAD and IA-2 autoantibodies. Am J Transplant 2012; 12: 
492-495 [PMID: 22151900 DOI: 10.1111/j.1600-6143.2011.0384
4.x]
17 Esmatjes E, Rodríguez-Villar C, Ricart MJ, Casamitjana R, 
Martorell J, Sabater L, Astudillo E, Fernández-Cruz L. Recur-
rence of immunological markers for type 1 (insulin-depen-
dent) diabetes mellitus in immunosuppressed patients after 
pancreas transplantation. Transplantation 1998; 66: 128-131 
[PMID: 9679835 DOI: 10.1097/00007890-199807150-00022]
18 Petruzzo P, Andreelli F, McGregor B, Lefrançois N, Dawahra 
M, Feitosa LC, Dubernard JM, Thivolet C, Martin X. Evidence 
of recurrent type I diabetes following HLA-mismatched pan-
creas transplantation. Diabetes Metab 2000; 26: 215-218 [PMID: 
10880896]
19 Braghi S, Bonifacio E, Secchi A, Di Carlo V, Pozza G, Bosi E. 
Modulation of humoral islet autoimmunity by pancreas allo-
transplantation influences allograft outcome in patients with 
type 1 diabetes. Diabetes 2000; 49: 218-224 [PMID: 10868938 
DOI: 10.2337/diabetes.49.2.218]
20 Thivolet C, Abou-Amara S, Martin X, Lefrancois N, Petru-
zzo P, McGregor B, Bosshard S, Dubernard JM. Serological 
markers of recurrent beta cell destruction in diabetic patients 
undergoing pancreatic transplantation. Transplantation 2000; 
69: 99-103 [PMID: 10653387 DOI: 10.1097/00007890-20000115
0-00018]
21 Pugliese A, Reijonen HK, Nepom J, Burke GW 3rd. Recur-
rence of autoimmunity in pancreas transplant patients: re-
search update. Diabetes Manag (Lond) 2011; 1: 229-238 [PMID: 
21927622 DOI: 10.2217/dmt.10.21]
22 Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Re-
currence of autoreactive antigen-specific CD4+ T cells in 
autoimmune diabetes after pancreas transplantation. Clin 
Immunol 2008; 128: 23-30 [PMID: 18455963 DOI: 10.1016/
j.clim.2008.03.459]
23 Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-
Pagola A, Molano RD, Diamantopoulos S, Standifer N, Geu-
btner K, Falk BA, Ichii H, Takahashi H, Snowhite I, Chen Z, 
Mendez A, Chen L, Sageshima J, Ruiz P, Ciancio G, Ricordi 
C, Reijonen H, Nepom GT, Burke GW, Pugliese A. Recur-
rence of type 1 diabetes after simultaneous pancreas-kidney 
transplantation, despite immunosuppression, is associated 
with autoantibodies and pathogenic autoreactive CD4 T-cells. 
Diabetes 2010; 59: 947-957 [PMID: 20086230 DOI: 10.2337/
db09-0498]
24 Brooks-Worrell B, Palmer JP. Prevention versus intervention 
of type 1 diabetes. Clin Immunol 2013; 149: 332-338 [PMID: 
23803322 DOI: 10.1016/j.clim.2013.05.018]
25 Martins LS, Henriques AC, Fonseca IM, Rodrigues AS, Oli-
verira JC, Dores JM, Dias LS, Cabrita AM, Silva JD, Noronha 
IL. Pancreatic autoantibodies after pancreas-kidney trans-
plantation - do they matter? Clin Transplant 2014; 28: 462-469 
[PMID: 24655222 DOI: 10.1111/ctr.12337]
186 September 24, 2014|Volume 4|Issue 3|WJT|www.wjgnet.com
Martins LS. Autoimmune diabetes recurrence in pancreas transplants
26 Martins L, Malheiro J, Henriques AC, Dias L, Dores J, Olivei-
ra F, Seca R, Almeida R, Sarmento AM, Cabrita A, Teixeira 
M. Pancreas-kidney transplantation and the evolution of 
pancreatic autoantibodies. Transplant Proc 2009; 41: 913-915 
[PMID: 19376387 DOI: 10.1016/j.transproceed.2009.01.068]
27 Abreu JR, Roep BO. Immune monitoring of islet and pan-
creas transplant recipients. Curr Diab Rep 2013; 13: 704-712 
[PMID: 23943207 DOI: 10.1007/s11892-013-0399-3]
28 Wenzlau JM, Hutton JC. Novel diabetes autoantibodies and 
prediction of type 1 diabetes. Curr Diab Rep 2013; 13: 608-615 
[PMID: 23900975 DOI: 10.1007/s11892-013-0405-9]
29 Ringers J, van der Torren CR, van de Linde P, van der Boog 
PJ, Mallat MJ, Bonifacio E, Roep BO, de Fijter JW. Pretrans-
plantation GAD-autoantibody status to guide prophylactic 
antibody induction therapy in simultaneous pancreas and 
kidney transplantation. Transplantation 2013; 96: 745-752 
[PMID: 23912172 DOI: 10.1097/TP.0b013e3182a012cc]
30 Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, 
Atkinson MA, Roep BO, von Herrath MG. Demonstration of 
islet-autoreactive CD8 T cells in insulitic lesions from recent 
onset and long-term type 1 diabetes patients. J Exp Med 2012; 
209: 51-60 [PMID: 22213807 DOI: 10.1084/jem.20111187]
31 Abreu JR, Roep BO. Targeting proinsulin-reactive CD8+ T 
cells: a new direction for type 1 diabetes treatment. Expert 
Rev Clin Immunol 2013; 9: 1001-1003 [PMID: 24168405 DOI: 
10.1586/1744666X.2013.852958]
P- Reviewer: Marek-Trzonkowska N, Senior PA 
S- Editor: Wen LL    L- Editor: A    E- Editor: Liu SQ 
187 September 24, 2014|Volume 4|Issue 3|WJT|www.wjgnet.com
Martins LS. Autoimmune diabetes recurrence in pancreas transplants
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
